中国药业2017，Vol.26Issue(12)：53-55,3.DOI:10.3969/j.issn.1006-4931.2017.12.015
培美曲塞或紫杉醇联合奈达铂一线治疗肺腺癌临床评价
Clinical Evaluation of Pemetrexed or Taxol Combined with Nedaplatin in First-Line Treatment of Lung Adenocarcinoma
周英文 1周玉福 1张莉梅1
作者信息
- 1. 重庆市北碚区妇幼保健院,重庆 400700
- 折叠
摘要
Abstract
Objective To compare the efficacy of Pemetrexed combined with Nedaplatin and Taxol combined with Nedaplatin in the treatment of lung adenocarcinoma. Methods Totally 69 patients with advanced lung adenocarcinoma admitted to a 3A hospital were randomly divided into group A (35 cases ) and group B (34 cases ) ,the group A was given Pemetrexed combined with Nedaplatin for chemotherapy,while the group B was given Taxol combined with Nedaplatin for chemotherapy. Results The complete remission rate, partial remission rate and overall survival rate in the A group were 45. 71%,34. 29% and 80. 00%,which were obviously higher than 26. 47%,23. 53% and 50. 00% in the group B,the rate of progression in the group A was significantly lower than that in the group B. The incidence rate of Ⅰ-Ⅳ grade myelosuppression in the group A and the group B was 47. 06% and 82. 86%,respectively,all the differences were statistically significant (P < 0. 05 ) . There was no significant difference in other toxic reactions between the two groups. Conclusion Pemetrexed combined with nedaplatin in first-line treatment of lung adenocarcinoma has better efficacy,but the patients can′t resist to the chemotherapy adverse reactions such as myelosuppression in the second-line treatment.关键词
培美曲塞/紫杉醇/奈达铂/肺腺癌/一线治疗Key words
Pemetrexed/Taxol/Nedaplatin/lung adenocarcinoma/first-line treatment分类
医药卫生引用本文复制引用
周英文,周玉福,张莉梅..培美曲塞或紫杉醇联合奈达铂一线治疗肺腺癌临床评价[J].中国药业,2017,26(12):53-55,3.
